13. Multiple sclerosis/Neuromyelitis optica
3,050 clinical trials,   2,147 drugs   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-001643-20-SE
(EUCTR)
03/07/201519/01/2015Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple SclerosisA Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Nervous System Diseases
MedDRA version: 17.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500
Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes
168Phase 2Germany;Italy;Switzerland;Sweden;United States;Czech Republic;Mexico;Canada;Poland;Russian Federation
2EUCTR2014-003265-19-PL
(EUCTR)
12/05/201526/02/2015Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839 Relapsing-remitting multiple sclerosis
MedDRA version: 18.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500
Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes
168Phase 2United States;Czech Republic;Mexico;Canada;Poland;Russian Federation;Germany;Italy;Switzerland;Sweden
3EUCTR2014-001643-20-DE
(EUCTR)
10/02/201518/08/2014Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple SclerosisA Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Nervous System Diseases
MedDRA version: 18.0;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500
Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500
Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500
Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes
168Phase 2United States;Czech Republic;Mexico;Canada;Poland;Russian Federation;Germany;Italy;Switzerland;Sweden
4NCT02306811
(ClinicalTrials.gov)
February 20151/12/2014Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839Relapsing-remitting Multiple SclerosisDrug: VatelizumabGenzyme, a Sanofi CompanyNULLTerminated18 YearsN/ABoth62Phase 2United States;Canada;Poland;Russian Federation
5EUCTR2014-001643-20-PL
(EUCTR)
23/01/201531/10/2014Efficacy and Safety of Vatelizumab in Patients with Relapsing Remitting Multiple SclerosisA Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Nervous System Diseases
MedDRA version: 18.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Code: SAR339658
INN or Proposed INN: Vatelizumab
Other descriptive name: CHR-1103 / GBR500
Genzyme CorporationNULLNot RecruitingFemale: yes
Male: yes
168Phase 2United States;Czech Republic;Mexico;Canada;Poland;Russian Federation;Germany;Italy;Switzerland;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT02222948
(ClinicalTrials.gov)
September 201420/8/2014Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple SclerosisA Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)Relapsing-remitting Multiple SclerosisDrug: Vatelizumab;Drug: Placebo (for Vatelizumab)Genzyme, a Sanofi CompanyNULLTerminated18 Years55 YearsBoth112Phase 2United States;Canada;Poland;Russian Federation;Sweden